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Chronic cold urticaria (ColdU) is a rare disease charac-
terized by mast cell-mediated wheals and angioedema 
following cold exposure. Second-generation H1-anti-
histamines, such as rupatadine, are the recommended 
first-line therapy. As of yet, the effects of rupatadine 
up-dosing on development of ColdU symptom have only 
been partially characterized. Two-centre, randomized, 
double-blind, 3-way crossover, placebo-controlled study 
in patients with a confirmed ColdU was designed to as-
sess the effects of up-dosing of rupatadine. A total of 23 
patients were randomized to receive placebo, rupatadine 
20 mg/day, and rupatadine 40 mg/day for 1 week. The 
primary outcome was change in critical temperature 
thresholds and critical stimulation time thresholds af-
ter treatment. Secondary endpoints included assessment 
of safety and tolerability of rupatadine. Both 20 and 40 
mg rupatadine were highly effective in reducing critical 
temperature thresholds (p < 0.001) and critical stimula-
tion time thresholds (p < 0.001). In conclusion, rupata-
dine 20 and 40 mg significantly reduced the development 
of chronic cold urticaria symptom without an increase 
in adverse effects. Key words: rupatadine; chronic cold 
urticarial; H1-antihistamine; up-dosing.
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Chronic cold urticaria (ColdU) is a rare, but severe and 
potentially life-threatening, form of chronic physical 
urticaria in which, in addition to urticarial wheals, angi-
oedema and anaphylaxis may also occur after ingestion 
of cold foods or extended exposure to cold (1). However, 
patients exhibit a wide variability in terms of the risk of 
systemic symptoms and even life-threatening compli-
cations when untreated or undertreated. It is essential, 
therefore, to be able to predict the potential risk that each 
individual patient faces and how this may be ameliorated 
by therapy (2).
To assist with the diagnosis of ColdU, guidelines 
published by EAACI/GA2LEN/EDF/WAO1 recommend 
provocation testing by applying a cold stimulus to the 
skin, usually the volar forearm. Traditionally, this has 
been done by applying an ice cube to the skin or testing 
with cool packs or cold-water baths (3, 4). However, 
while these techniques assist in diagnosis, they do not 
provide information about temperature and stimulation 
time thresholds at which patients will start to develop 
symptoms. This knowledge is essential in order to es-
tablish disease severity and monitor the effectiveness 
of treatment. The critical temperature threshold (CTT) 
at which a patient starts to develop symptoms may be 
determined by using TempTest® 3.0, a Peltier effect-
based electronic device for simultaneous provocation 
of 12 discrete 10 mm2 areas of the skin, with tempe-
ratures ranging from 4°C to 26°C and an accuracy of 
< 2°C (5). Alternatively, the critical stimulation time 
threshold (CsTT) may be evaluated by exposing the 
skin to 4°C and assessing the development of wheals 
at 30-s intervals from 0.5 to 5 min.
The first-line therapy in ColdU recommended by 
the current EAACI/GA2LEN/EDF/WAO guidelines 
is symptomatic relief with second-generation H1-
antihistamines. If standard doses are not effective 
the guidelines recommend increasing the dosage up 
to 4-fold in order to better control the symptoms (6). 
Recent data have shown that the use of high doses of 
second-generation antihistamines is significantly more 
effective in ColdU than standard dose treatment (7–9). 
Rupatadine is a potent second-generation antihista-
mine approved for the treatment of the symptoms of 
allergic rhino-conjunctivitis and urticaria that has also 
been shown to possess anti-platelet-activating factor 
(PAF) activity (10, 11). Clinical trials in allergic rhini-
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tis and chronic urticaria have shown rupatadine to be 
well tolerated and free from untoward cardiovascular, 
cognitive or psychomotor effects (12, 13), all important 
properties for a drug to be used in higher doses. 
The aim of this study was to assess the efficacy of 
2-fold and 4-fold dose increments from the licensed dose 
of rupatadine against the development of symptoms of 
ColdU following provocation with TempTest® 3.0. The 
outcome measures were changes in CTT and CsTT. 
MATERIALS AND METHODS (see Appendix S12)
RESULTS
The effects of rupatadine vs. placebo were tested in a 
3-way crossover, double-blind trial (Fig. 1). Although 
24 patients were enrolled in the study, one dropped 
out for personal reasons unrelated to the study drug. 
Consequently, data analysis has been performed on 
the remaining 23 patients. The estimation of CsTT 
on 40 mg rupatadine was lost for one patient due to a 
technical error.
Effect of rupatadine on critical temperature thresholds
Fig. 2a shows the CTTs for patients having taken pla-
cebo, rupatadine 20 mg or rupatadine 40 mg for one 
week. The median CTT for the production of wheals 
for the placebo group was 14°C (range < 4°C to 24°C). 
The median CTT for rupatadine 20 mg and 40 mg were 
10°C (range < 4°C to 24°C) and 4°C (range < 4°C to 
24°C), respectively. Both of these median values were 
significantly (p < 0.001) lower than that of placebo. 
There was no significant difference between drug doses.
Responder analysis (Fig. 2b) shows that 7/23 (30%) 
and 11/22 (50%) patients were wheal-free on provoca-
tion following treatment with 20 and 40 mg rupatadine, 
respectively, after one week of treatment. Adding partial 
responders as well (patients whose CTT decreased by 
≥ 4°C) showed responder rates of 17/23 (74%) and 
18/22 (81%) for treatment with 20 and 40 mg rupata-
dine, respectively.
Effect of rupatadine on critical stimulation time thresholds
Fig. 3a shows the CsTTs for patients having taken pla-
cebo, rupatadine 20 mg or rupatadine 40 mg for one 
week. The median CsTT for the production of wheals for 
the placebo group was 1.5 (1–>5) min. The median CsTT 
for rupatadine 20 and 40 mg were 3.0 (1–> 5) and 5.0 
(1–> 5) min, respectively. Both of these median values 
were significantly (p < 0.001) greater than that of placebo. 
There was no significant difference between drug doses.
Responder analysis (Fig. 3b) shows that 9/23 (39%) 
and 11/22 (50%) patients were symptom-free on pro-
vocation following treatment with 20 and 40 mg rupa-
tadine, respectively. Adding partial responders (patients 
whose CsTT increased by ≥ 0.5 min), showed responder 
rates of 15/23 (65%) and 18/22 (81%) for treatment with 
20 and 40 mg rupatadine, respectively.
Safety assessments 
A total of 25 adverse events (AEs) were reported and 
distributed by treatment groups as follows: placebo 
(n = 7), rupatadine 20 mg (n = 7) and rupatadine 40 mg 
(n = 11). The distribution of the number of patients with 
at least one AE was not statistically different between 
treatment groups. Only one patient reported somnolence 
related with 40 mg dose. Few patients reported headache 
(2 cases with placebo, 1 with 20 mg, and 1 with 40 mg 
rupatadine). Other AEs, included tiredness (1 case with 
placebo and 2 with 40 mg), cold (2 cases with placebo, 
2 with 20 mg, 1 with 40 mg) and 1 increase in liver 
enzymes with 40 mg. No electrocardiography (ECG) 
changes were seen. All of these AEs were not considered 
to be drug-related. All AEs resolved spontaneously and 
no patients withdrew from the study because of them. 
One serious AE (thoracic vertebra fracture) occurred in 
one patient during the treatment with rupatadine 40 mg, 
for which the patient was hospitalized and recovered. 
This AE was considered as not related to the study drug. 
DISCUSSION
This trial has confirmed previous studies (2, 9, 16) 
where rupatadine improved clinical symptoms in 
ColdU with doses of 20 mg and shows how also 40 
mg daily for one week is highly significant compared 
with placebo in reducing wheal formation following 
cold provocation. Furthermore, the safety profile of the 
drug appeared excellent at both doses.
Fig. 1. Study design. RU: rupatadine; S: screening visit; R: randomization 
visit; V1, V2 and V3: visit at which critical temperature and stimulation 
time thresholds were determined and safety was evaluated.
2http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2150
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This study measured provocation thresholds by 2 
methods, assessment of the temperature threshold for 
whealing and the time taken for provocation at 4°C to 
induce wheals. Analysis by Spearman’s rank correlation 
analysis showed these methods to be highly correlated 
(p < 0.001) in all treatment groups. Furthermore, the 
observation that treatment with 20 mg rupatadine re-
sulted in 9/23 (39%) patients being symptom-free is not 
significantly different from the 11/21 (52%) symptom-
free patients reported by Metz et al. (9) using an ice 
cube test for provocation.
The lower dose of 20 mg rupatadine was chosen 
because of its demonstrated greater effectiveness than 
the 10 mg dose in reducing chronic urticaria symptoms 
(13) and the effectiveness of this dose in 3 previous 
ColdU studies (2, 9, 16). This dose also afforded highly 
significant protection in this study. While not statisti-
cally significant, there were more patients partially and 
completely symptom-free following treatment with 40 
mg rupatadine.
Three patients (13%) of 23 did not show clinical 
improvement on up-dosing of rupatadine. These obser-
vations are consistent with other antihistamines, such 
as desloratadine (4/15 non-responders) (17), rupatadine 
(3/21 non-responders) (9) and bilastine (1/20 non-
responder) (8). While the reasons for this are not known, 
Fig. 2. (a) Critical temperature thresholds 
(CTTs) for the production of wheals following 
cold provocation. Horizontal lines indicate 
medians. The levels of significance values are for 
differences in the median CTTs calculated using 
Wilcoxon non-parametric test. (b) Rupatadine 
treatment protects from cold-induced wheal 
responses. Considering the CTT response 
assessed after each treatment period all patients 
were divided into 3 groups: complete responders 
(no evidence of a whealing response at 4°C, 
green column), partial responders (reduction in 
CTT ≥ 4°C, orange column) and non-responders 
(reduction in CTT less than 4°C, pink column).
Fig. 3. (a) Critical stimulation time threshold 
(CsTTs) for the production of wheals following 
cold provocation. Horizontal lines indicate 
medians. The levels of significance values are 
for differences in the median CsTTs calculated 
using Wilcoxon non-parametric test. (b) 
Considering the CsTT response assessed after 
each treatment period all patients were divided 
into 3 groups: complete responders (no evidence 
of a whealing response after 5 min provocation 
with 4°C, green column), partial responders 
(reduction in CsTT ≥ 0.5 min, orange column) 
and non-responders (reduction in CsTT < 0.5 
min, pink column).
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it suggests that, as in other forms of urticaria (6), there 
is a subgroup ColdU patients who do not respond to 
H1-antihistamines. Further studies are needed to better 
characterize these patients. 
In conclusion, this study has contributed importantly 
to our understanding of the use of H1-antihistamines in 
ColdU. As we have shown, rupatadine is highly effec-
tive in reducing the symptoms of ColdU. Increasing the 
dose to 20 and 40 mg daily appears to increase effecti-
veness of the drug without showing increased sedation 
or an increase in other unwanted effects. 
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